Rchr
J-GLOBAL ID：202201010453346419
Update date: Apr. 11, 2024
Suzuki Shinichiro
スズキ シンイチロウ | Suzuki Shinichiro
Affiliation and department：
Job title：
Assistant professor
Research theme for competitive and other funds (2)：
- 2022 - 2025 Analysis of the risk factors for the development and severity of immune-related adverse events by immune checkpoint inhibitors
- 2021 - 2025 Exploring mechanism underlying resistance to kras inhibitor
Papers (18)：
-
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, et al. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society. 2023. 20. 2. 281-289
-
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, et al. Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society. 2023. 20. 2. 290-290
-
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, Hiroaki Kanemura, Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, Yasuharu Haku, Katsuhiro Ito, et al. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. Frontiers in immunology. 2023. 14. 1325462-1325462
-
米阪 仁雄, 高濱 隆幸, 黒崎 隆, 川中 雄介, 金村 宙昌, 磯本 晃佑, 鈴木 慎一郎, 三谷 誠一郎, 中川 和彦, 白石 直樹, et al. がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定. 肺癌. 2022. 62. 5. 439-439
-
Hiroaki Kanemura, Hidetoshi Hayashi, Shuta Tomida, Junko Tanizaki, Shinichiro Suzuki, Yusuke Kawanaka, Asuka Tsuya, Yasushi Fukuda, Hiroyasu Kaneda, Keita Kudo, et al. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC. JTO clinical and research reports. 2022. 3. 8. 100373-100373
ｍore...
MISC (2)：
-
金村 宙昌, 竹原 俊幸, 小野寺 勇太, 寺村 岳士, 鈴木 慎一郎, 坂井 和子, 西尾 和人, 中川 和彦, 林 秀敏, 米阪 仁雄. PTPRRを介したEGFR活性化に起因するKRASG12C阻害薬耐性の克服(Combating acquired resistance to KRAS inhibitors in NSCLC by targeting PTPRR-mediated activation of EGFR signaling). 日本癌学会総会記事. 2023. 82回. 422-422
-
米阪仁雄, 稲垣千昌, 稲垣千昌, 高濱隆幸, 高濱隆幸, 白石直樹, 磯本晃佑, 金村宙昌, 鈴木慎一郎, 谷崎潤子, et al. Providing Anti-Lung Cancer Drug Therapy Based on Genetic Information by Comprehensive Genomic Profiling. 日本癌学会学術総会抄録集(Web). 2023. 82nd
Professional career (1)：
- PhD. M.D. (Kindai University)
Return to Previous Page
